EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Bimodal Dissolving Microneedles with Nanoparticle Coating and Encapsulation for Extended Dual‐Drug Delivery

Mingshan Li, Akmal H B Sabri, Nuoya Qin, Ke Peng, Marco Abbate, Alejandro J Paredes, Helen O McCarthy, Lalitkumar K Vora, Ryan F Donnelly iD

Small · 2025

DOI: 10.1002/smll.202502904 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Small, 2025. Verfasst von Mingshan Li und 8 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Medical Biology Centre, Queen's University Belfast, 97 Lisburn Road, Belfast, BT9 7BL, Northern Ireland, UK. Hauptthemen laut MEDLINE: Needles, Drug Delivery Systems, Nanoparticles. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 71 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Effective co‐delivery of multiple drugs via microneedle (MN) platforms is challenging due to limited loading capacity and the need for sustained release. This study presents a bimodal coated‐dissolving microneedle (DMN) patch for extended delivery of diclofenac (DCF) and dexamethasone (DSP) nanoparticles to treat osteoarthritis. The DMN tips are loaded with DCF nanoparticles (3.84 mg/patch) and coated with DSP‐PLGA nanosuspensions (0.44 mg/patch), achieving dual‐drug release from a single patch. Ex vivo studies in neonatal porcine skin show > 90% penetration into the stratum corneum (≈276 µm depth), with transdermal delivery of 1.54 mg DCF and 118 µg DSP at 24 h. In vivo pharmacokinetic studies in rats demonstrate sustained DCF plasma levels for 72 h, with an extended half‐life (13.0 h) and 80.3% relative bioavailability compared to oral dosing. DSP exhibits a biphasic release, peaking at 24–30 h (227.7 ng mL −1 , 63.9% bioavailability). High drug levels persist in skin and paw tissues for 72 h, suggesting prolonged local efficacy. These bimodal DMNs provide a high‐loading, sustained‐release platform for minimally invasive, patient‐friendly dual‐drug therapy, optimizing osteoarthritis treatment and improving compliance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeedlesDrug Delivery SystemsNanoparticlesAnimalsDexamethasoneDiclofenacSwineRatsRats, Sprague-DawleyAdministration, CutaneousBiological Availability

Stichwörter der Autor:innen

bimodaldexamethasonediclofenacmicroneedlesnanocrystalsosteoarthritistransdermal delivery

Substanzen

DexamethasoneDiclofenac

Autor:innen und Institutionen

  • School of Pharmacy, Medical Biology Centre, Queen's University Belfast, 97 Lisburn Road, Belfast, BT9 7BL, Northern Ireland, UK.
  • Division of Advanced Materials and Healthcare Technologies, School of Pharmacy, The University of Nottingham, Nottingham, NG7 2RD, UK.

ORCID-Profile: Ryan F Donnelly

Zitieren

APA

Li, M., Sabri, A. H. B., Qin, N., Peng, K., Abbate, M., Paredes, A. J., McCarthy, H. O., Vora, L. K., & Donnelly, R. F. (2025). Bimodal Dissolving Microneedles with Nanoparticle Coating and Encapsulation for Extended Dual‐Drug Delivery. Small. https://doi.org/10.1002/smll.202502904

Vancouver

Li M, Sabri AHB, Qin N, Peng K, Abbate M, Paredes AJ, et al. Bimodal Dissolving Microneedles with Nanoparticle Coating and Encapsulation for Extended Dual‐Drug Delivery. Small. 2025. doi:10.1002/smll.202502904

BibTeX
@article{Li2025,
  author = {Li, Mingshan and Sabri, Akmal H B and Qin, Nuoya and Peng, Ke and Abbate, Marco and Paredes, Alejandro J and McCarthy, Helen O and Vora, Lalitkumar K and Donnelly, Ryan F},
  title = {Bimodal Dissolving Microneedles with Nanoparticle Coating and Encapsulation for Extended Dual‐Drug Delivery},
  journal = {Small},
  year = {2025},
  doi = {10.1002/smll.202502904}
}
Kostenlos starten →